Skip to main content
. 2022 Mar 21;11(6):1734. doi: 10.3390/jcm11061734
AR Androgen receptor
ATR Ataxia telangiectasia and rad3-related kinase
CTCs Circulating tumor cells
ctDNA Circulating tumor DNA
DSB Double strand break
EAU European Association of Urology
ESMO European Society of Medical Oncology
FANC Fanconi Anemia
FDA Food and Drug Administration
HR Hazard ratio
HRD Homologous recombination deficiency
HRR Homologous recombination repair
mCRPC Metastatic castration-resistant prostate cancer
mCSPC Metastatic castration-sensitive prostate cancer
MMR Mismatch repair
NCCN National Comprehensive Cancer Network
NGS Next-generation screening
NHT Next-generation hormonal therapy
ORR Objective radiological response
OS Overall survival
PARP Poly-ADP-ribose polymerase
PARPi PARP inhibitor
PCa Prostate cancer
PFS Progression-free survival
RECIST Response Evaluation Criteria in Solid Tumors
rPFS Radiological progression-free survival
SSB Single strand break